ABMD:NSD-Abiomed Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 253.79

Change

-0.37 (-0.15)%

Market Cap

USD 11.58B

Volume

0.29M

Avg Analyst Target

USD 297.33 (+17.16%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Abiomed Inc (ABMD) Stock Analysis:
Based on the Abiomed Inc stock forecasts from 3 analysts, the average analyst target price for Abiomed Inc is USD 297.33 over the next 12 months. Abiomed Inc’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Abiomed Inc is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, Abiomed Inc’s stock price was USD 253.79. Abiomed Inc’s stock price has changed by +8.41% over the past week, -17.08% over the past month and -5.28% over the last year.

About

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with int ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

-10.14 (-3.03%)

USD32.85B 171.14 77.12
ALGN Align Technology Inc

-1.32 (-0.48%)

USD21.71B 31.02 18.18
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
PODD Insulet Corporation

-2.15 (-1.08%)

USD13.80B 829.42 84.91
BRKR Bruker Corporation

-0.66 (-1.10%)

USD8.99B 33.27 17.75
SWAV ShockWave Medical Inc

+1.24 (+0.76%)

USD5.81B N/A 138.45
IART Integra LifeSciences Holdings ..

+0.39 (+0.66%)

USD4.93B 32.22 16.98
TNDM Tandem Diabetes Care Inc

-1.89 (-2.56%)

USD4.72B 307.71 186.72
IRTC iRhythm Technologies Inc

-6.04 (-4.34%)

USD3.93B N/A N/A
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67

ETFs Containing ABMD

Symbol Name Weight Mer Price(Change) Market Cap
CHEP AGFiQ U.S. Market Neutral.. 0.00 % 1.42 %

N/A

USD0.75M
MOM AGFiQ U.S. Market Neutral.. 0.00 % 2.58 %

N/A

USD4.73M
SLIM The Obesity ETF 0.00 % 0.35 %

N/A

USD0.01B
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

-0.03 (-0.10%)

USD0.06B
BMED BlackRock Future Health E.. 0.00 % 0.85 %

+0.13 (+0.57%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -29.34% 64% D 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.34% 64% D 41% F
Trailing 12 Months  
Capital Gain -5.28% 86% B 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.28% 86% B 67% D+
Trailing 5 Years  
Capital Gain 94.42% 78% C+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 94.42% 78% C+ 79% C+
Average Annual (5 Year Horizon)  
Capital Gain 28.98% 59% F 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.98% 59% F 80% B-
Risk Return Profile  
Volatility (Standard Deviation) 66.14% 46% F 22% F
Risk Adjusted Return 43.82% 72% C- 72% C-
Market Capitalization 11.58B 97% A+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 85.29 23% F 11% F
Price/Book Ratio 7.70 17% F 10% F
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA 42.14 29% F 14% F
Management Effectiveness  
Return on Equity 9.64% 88% B+ 65% D
Return on Invested Capital 6.12% 80% B- 65% D
Return on Assets 10.13% 96% A 92% A-
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 4.10 63% D 40% F
Short Percent 2.82% 63% D 51% F
Beta 1.33 40% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.